Toshio Tanaka Selected Research

tocilizumab (atlizumab)

1/2021	Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19.
1/2020	IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
1/2018	Interleukin (IL-6) Immunotherapy.
1/2016	Immunotherapeutic implications of IL-6 blockade for cytokine storm.
3/2015	Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.
1/2015	Therapeutic uses of anti-interleukin-6 receptor antibody.
1/2015	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
9/2014	IL-6 in inflammation, immunity, and disease.
4/2014	The biology and medical implications of interleukin-6.
3/2014	Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toshio Tanaka Research Topics

Disease

22	Rheumatoid Arthritis 01/2019 - 08/2006
14	Neoplasms (Cancer) 02/2021 - 08/2007
12	Infections 01/2020 - 11/2004
11	Inflammation (Inflammations) 01/2020 - 06/2003
9	Castleman Disease (Castleman's Disease) 01/2018 - 12/2011
9	Arthritis (Polyarthritis) 01/2018 - 01/2009
9	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2018 - 12/2011
8	Wounds and Injuries (Trauma) 01/2018 - 01/2014
6	Asthma (Bronchial Asthma) 01/2019 - 04/2006
6	Obesity 08/2015 - 09/2011
6	Leukemia 06/2015 - 03/2002
5	COVID-19 01/2022 - 01/2020
4	Cytokine Release Syndrome 01/2022 - 01/2015
4	Sepsis (Septicemia) 11/2021 - 01/2016
4	Atopic Dermatitis (Atopic Eczema) 01/2019 - 08/2004
4	Hypersensitivity (Allergy) 01/2019 - 01/2014
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2017 - 02/2007
4	Systemic Scleroderma (Systemic Sclerosis) 01/2016 - 12/2010
4	Intracranial Vasospasm 10/2009 - 01/2002
3	Critical Illness (Critically Ill) 08/2021 - 01/2020
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2020 - 08/2007
3	Myocardial Infarction 01/2020 - 05/2008
3	Seasonal Allergic Rhinitis (Hay Fever) 10/2019 - 01/2009
3	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 01/2018 - 01/2015
3	Acute-Phase Reaction 01/2016 - 02/2014
3	Autoimmune Diseases (Autoimmune Disease) 02/2014 - 12/2011
3	Polymyositis 01/2012 - 02/2007
3	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 10/2009 - 01/2002
2	Hypertension (High Blood Pressure) 01/2021 - 11/2010
2	Burns 01/2020 - 01/2019
2	Cardiotoxicity 03/2019 - 02/2015
2	Anaphylaxis (Anaphylactic Shock) 01/2019 - 01/2014
2	Food Hypersensitivity (Food Allergy) 01/2019 - 01/2014
2	Choroidal Neovascularization 03/2017 - 10/2010
2	Chronic Disease (Chronic Diseases) 01/2017 - 01/2014
2	Body Weight (Weight, Body) 08/2015 - 10/2010
2	Prostatic Neoplasms (Prostate Cancer) 12/2014 - 01/2014
2	Systemic Juvenile Rheumatoid Arthritis 04/2014 - 02/2014
2	Medulloblastoma 09/2012 - 09/2012
2	Mycoses (Diseases, Fungus) 01/2012 - 10/2006
2	Psoriatic Arthritis 01/2012 - 01/2012
2	Vasculitis (Vasculitides) 01/2012 - 01/2006
2	Tuberculosis (Tuberculoses) 04/2010 - 08/2006
2	Vascular Remodeling 05/2008 - 07/2006
2	Hypoxia (Hypoxemia) 05/2008 - 01/2002
2	Heart Failure 05/2008 - 09/2004
2	Cardiovascular Diseases (Cardiovascular Disease) 05/2008 - 07/2002
2	Fever (Fevers) 01/2006 - 03/2005
2	Pain (Aches) 01/2006 - 03/2005
1	Disseminated Intravascular Coagulation 11/2021

Drug/Important Bio-Agent (IBA)

31	tocilizumab (atlizumab)FDA Link 01/2021 - 12/2009
28	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2005
14	Pharmaceutical PreparationsIBA 02/2020 - 01/2002
11	CytokinesIBA 01/2022 - 06/2003
8	Proteins (Proteins, Gene)FDA Link 01/2014 - 07/2002
7	Monoclonal AntibodiesIBA 01/2020 - 01/2012
7	FlavonoidsIBA 01/2019 - 06/2007
5	AntibodiesIBA 11/2017 - 11/2004
5	Biological ProductsIBA 03/2014 - 01/2012
5	Messenger RNA (mRNA)IBA 01/2014 - 01/2002
4	C-Reactive ProteinIBA 08/2021 - 01/2006
4	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2019 - 01/2012
4	AntigensIBA 11/2017 - 04/2010
4	AutoantibodiesIBA 11/2017 - 05/2002
4	Tumor Necrosis Factor InhibitorsIBA 01/2014 - 11/2010
3	Interleukin-8 (Interleukin 8)IBA 11/2021 - 01/2018
3	Interleukin-10 (Interleukin 10)IBA 11/2021 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 11/2019 - 02/2007
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 11/2004
2	Oxygen (Dioxygen)IBA 08/2021 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 08/2011
2	Immune Checkpoint InhibitorsIBA 05/2020 - 11/2019
2	Interferon-gamma (Interferon, gamma)IBA 05/2020 - 11/2019
2	InterleukinsIBA 01/2020 - 01/2012
2	Plasminogen Activator Inhibitor 1IBA 01/2020 - 01/2018
2	Plasminogen Activators (Plasminogen Activator)IBA 01/2020 - 04/2016
2	AllergensIBA 10/2019 - 01/2018
2	Peptides (Polypeptides)IBA 10/2019 - 02/2014
2	Immunoglobulin E (IgE)IBA 01/2018 - 01/2009
2	AcidsIBA 03/2017 - 01/2012
2	Coloring Agents (Dyes)IBA 02/2016 - 03/2005
2	Antirheumatic Agents (DMARD)IBA 03/2014 - 11/2010
2	Amphotericin B (Amphotericin)FDA LinkGeneric 01/2012 - 10/2006
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2012 - 01/2012
2	allicinIBA 01/2012 - 10/2006
2	Alanine Transaminase (SGPT)IBA 11/2010 - 03/2005
2	EnzymesIBA 11/2010 - 10/2009
2	Imatinib Mesylate (Gleevec)FDA Link 10/2010 - 01/2009
2	Heme (Haem)IBA 10/2009 - 01/2002
2	isoquercitrinIBA 09/2009 - 01/2009
2	GlycosidesIBA 09/2009 - 01/2009
2	QuercetinIBA 09/2009 - 01/2009
2	OligodeoxyribonucleotidesIBA 05/2008 - 09/2004
2	Interleukin-13IBA 09/2007 - 06/2003
2	Interleukin-18 (Interleukin 18)IBA 09/2007 - 04/2006

Therapy/Procedure

16	Therapeutics 12/2020 - 05/2002
6	Heterologous Transplantation (Xenotransplantation) 01/2019 - 01/2014
3	Drug Therapy (Chemotherapy) 02/2021 - 01/2012
3	Off-Label Use 01/2015 - 02/2014
2	Oral Administration 01/2009 - 09/2004